Thermo Fisher Scientific Vadastuximab Chimeric Recombinant Human Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Human / IgG1, kappa

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Human CD33/SIGLEC3

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.39 mg/mL

Purification

Protein A

Storage buffer

PBS, pH 7.5

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2911244

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Vadastuximab is a biosimilar that targets CD33. CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies, and these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia. Further, CD33 is found on granulocyte and macrophage precursors in the bone marrow, but is not on pluripotent stem cells. CD33 is also expressed on, and is a useful marker for, peripheral monocytes. CD33 is useful for distinguishing myelogenous leukemia cells from lymphoid or erythroid leukemias. Diseases associated with CD43 dysfunction include gallbladder lymphoma and extracutaneous mastocytoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.